OYE Therapeutics will initiate clinical development of its caffeine injection

OYE header

FDA clears company’s Investigational New Drug application for OYE-101, which seeks to reverse effects of anesthesia CROWN POINT, Ind. — OYE Therapeutics, a clinical-stage biopharmaceutical company advancing novel therapies for perioperative, emergency and acute-care medicine, today (Feb. 2) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application […]

Subaru of Indiana Automotive expands commitment to sustainability with new 204 kW solar array at Lafayette production plant

picture of factory

(Subaru of Indiana Automotive photo) LAFAYETTE, Ind. – Subaru of Indiana Automotive (SIA), a recognized industry leader in environmental stewardship, has energized a 204-kilowatt rooftop solar project atop its new building expansion in Lafayette. The system went into service in August 2025 and represents the latest step in SIA’s multi-decade effort to reduce its carbon […]

OYE Therapeutics closes $5M convertible note round, advancing toward clinical development

CROWN POINT, Ind. — OYE Therapeutics Inc., a privately held biopharmaceutical company developing first-in-class intravenous caffeine-based therapies for anesthesia recovery and opioid-induced respiratory depression, has announced the successful close of its $5 million convertible note financing, positioning the company to enter clinical development. The company is headquartered at the Purdue Technology Center of Northwest Indiana. […]